🚀 VC round data is live in beta, check it out!
Antibiotice Valuation Multiples
Discover revenue and EBITDA valuation multiples for Antibiotice and similar public comparables like Lavipharm, Alector, Dishman Carbogen Amics, C4 Therapeutics and more.
Antibiotice Overview
About Antibiotice
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
Founded
1955
HQ
Employees
1.4K
Website
Sectors
Financials (FY)
EV
$335M
Antibiotice Financials
Antibiotice reported last fiscal year revenue of $149M and EBITDA of $27M.
In the same fiscal year, Antibiotice generated $98M in gross profit, $27M in EBITDA, and $12M in net income.
Revenue (LTM)
Antibiotice P&L
In the most recent fiscal year, Antibiotice reported revenue of $149M and EBITDA of $27M.
Antibiotice expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $149M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $98M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 66% | XXX | XXX | XXX |
| EBITDA | — | XXX | $27M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 9% | XXX | XXX | XXX |
| Net Profit | — | XXX | $12M | XXX | XXX | XXX |
| Net Margin | — | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $52M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Antibiotice Stock Performance
Antibiotice has current market cap of $283M, and enterprise value of $335M.
Market Cap Evolution
Antibiotice's stock price is $0.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $283M | -0.3% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAntibiotice Valuation Multiples
Antibiotice trades at 2.2x EV/Revenue multiple, and 12.3x EV/EBITDA.
EV / Revenue (LTM)
Antibiotice Financial Valuation Multiples
As of April 18, 2026, Antibiotice has market cap of $283M and EV of $335M.
Equity research analysts estimate Antibiotice's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Antibiotice has a P/E ratio of 23.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $283M | XXX | $283M | XXX | XXX | XXX |
| EV (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 12.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 23.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.4x | XXX | XXX | XXX |
| P/E | — | XXX | 23.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Antibiotice Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Antibiotice Margins & Growth Rates
Antibiotice's revenue in the last fiscal year declined by (4%).
Antibiotice's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Antibiotice Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Antibiotice Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Prelude Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Antibiotice M&A Activity
Antibiotice acquired XXX companies to date.
Last acquisition by Antibiotice was on XXXXXXXX, XXXXX. Antibiotice acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Antibiotice
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAntibiotice Investment Activity
Antibiotice invested in XXX companies to date.
Antibiotice made its latest investment on XXXXXXXX, XXXXX. Antibiotice invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Antibiotice
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Antibiotice
| When was Antibiotice founded? | Antibiotice was founded in 1955. |
| Where is Antibiotice headquartered? | Antibiotice is headquartered in Romania. |
| How many employees does Antibiotice have? | As of today, Antibiotice has over 1K employees. |
| Is Antibiotice publicly listed? | Yes, Antibiotice is a public company listed on Bucharest Stock Exchange. |
| What is the stock symbol of Antibiotice? | Antibiotice trades under ATB ticker. |
| When did Antibiotice go public? | Antibiotice went public in 1997. |
| Who are competitors of Antibiotice? | Antibiotice main competitors are Lavipharm, Alector, Dishman Carbogen Amics, C4 Therapeutics. |
| What is the current market cap of Antibiotice? | Antibiotice's current market cap is $283M. |
| What is the current revenue of Antibiotice? | Antibiotice's last fiscal year revenue is $149M. |
| What is the current EV/Revenue multiple of Antibiotice? | Current revenue multiple of Antibiotice is 2.2x. |
| Is Antibiotice profitable? | No, Antibiotice is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.